Abstract library

292 results for "proliferative index".
#70 The validity of Ki-67 as a prognostic indicator in patients with appendiceal carcinoid tumor
Introduction: Carcinoid tumors of the appendix are rare and often discovered incidentally through appendectomy. Most are clinically benign but may be associated with metastatic disease. Ki-67, a nuclear protein structurally associated with chromatin, is an excellent marker for measuring cell proliferation and it has been shown to correlate with the outcome in pancreatic and ileocecal carcinoids.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Eric Y Liu
Authors: Liu E, Telem D A, Hwang J, Warner R R P, ...
#182 Ki-67 (MIB-1) Proliferative Activity and Beta-Catenin Immunoexpression in Liver Metastases of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Assessment of liver metastases biology features associated with cell proliferation and adhesion has a strong prognostic impact in patients with gastroenteropancreatic (GEP) neuroendocrine carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD, PhD Vera V. Delektorskaya
#320 Predictors of Clinical Response to Everolimus in Patients with Well-differentiated Metastatic Pancreatic NETs
Introduction: Everolimus (E) is an mTOR inhibitor with promising antitumor activity in patients with NETs. Predictor factors of response could improve the clinical use of this compound.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Cristina De Martino
#1595 Pathological Features of High Proliferative Activity Neuroendocrine Tumor
Introduction: High Proliferative Activity Neuroendocrine Tumor (NET G3) is difficult to be distinguished from neuroendocrine carcinoma. However, there are differences in clinical treatment and prognosis between the two. So it is crucial to make an accurate pathological diagnosis.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Huilin Geng
Authors: Geng H, Shi S, ...
#132 Correlation of Ki-67 proliferative index with pathological features and outcome in pancreatic endocrine tumors
Introduction: Information on relationships between Ki-67 values and clinicopathological features in pancreatic endocrine tumors (PETs) is scant and comes mostly from a small series.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Alessandro Zerbi
#737 Impact of Ki-67 Proliferative Index on Survival in Patients with Typical and Atypical Pulmonary Carcinoids
Introduction: Currently pulmonary carcinoids are separated into typical and atypical tumors based on mitotic count and presence of necrosis, according to the WHO classification. Whereas for GEP NETs the ENETS Guidelines have been incorporated into the WHO classification and grading is based on mitotic counts and Ki-67 index, the use of the Ki-67 index for grading pulmonary carcinoids is still under debate.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Martina Rudelius
#1911 Histological Differentiation Provides Useful, Additive and Independent Prognostic Information to Proliferation Index in G2 and G3 Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
Introduction: The WHO 2010 classification has provided a valuable tool to stratify NEN prognosis based on an objective measure, the proliferation index. However, morphology and, in particular, tumor differentiation, is emerging again as a relevant feature that should not be dismissed due to its important clinical implications.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: MD-PhD Paula Jimenez-Fonseca
#96 Expression of components of the mTOR pathway in gastroenteropancreatic neuroendocrine tumors
Introduction: Recently, the mammalian target of rapamycin (mTOR) inhibitors have entered late phase clinical trials in a broad variety of solid human malignancies, including neuroendocrine tumors (NETs). Since these drugs will certainly be used as routine therapeutics in the near future, it is surprising that information on the exact expression patterns of mTOR and its downstream target 4EBP1 in NETs is still lacking.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Atsuko Kasajima
#344 Cell Cycle Phase Expression Profile Guided Selection of Proliferative Markers for Well-differentiated Small Intestinal Neuroendocrine Neoplasms
Introduction: Grading of neuroendocrine lesions is often determined by Ki-67 (immunostain), despite limited prognostic ability for this cell cycle marker in well-differentiated tumors (WDNETs) and carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
Authors: Lawrence B, Kidd M, Alaimo D, Svejda B, ...
#219 Predictive Factors of Tumor Control in Patients with Well-differentiated Digestive Endocrine Carcinomas (WDEC) Treated with Lanreotide
Introduction: Somatostatin analogues (SSA) are indicated in the control of secretory symptoms of digestive endocrine tumors. The antiproliferative effect of SSA was recently demonstrated (Rinke et al, JCO 2009).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Philippe Ruszniewski